Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study
Virginia Bellido, Cristina Abreu Padín, Andrei‐Mircea Catarig, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 17, pp. 4938-4938
Open Access | Times Cited: 17

Showing 17 citing articles:

Semaglutide and cancer: A systematic review and meta-analysis
Lakshmi Nagendra, BG Harish, Meha Sharma, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 9, pp. 102834-102834
Closed Access | Times Cited: 36
Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study
Raffaele Napoli, Cesare Berra, Andrei‐Mircea Catarig, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 6, pp. 1658-1667
Open Access | Times Cited: 25
Glycemic Control, Weight Management, Cardiovascular Safety, and Cost-Effectiveness of Semaglutide for Patients with Type 2 Diabetes Mellitus: A Rapid Review and Meta-analysis of Real-World Studies
Sihua Wang, Sheng Wang, Yan Wang, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 2, pp. 497-519
Open Access | Times Cited: 8
Once‐weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study
Kamel Mohammedi, Narimène Belhatem, Tina Landsvig Berentzen, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 7, pp. 1855-1864
Open Access | Times Cited: 15
Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study
Manel Pladevall, Ryan Ziemiecki, Catherine B. Johannes, et al.
Diabetes Therapy (2025)
Open Access
Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)
JAMES AMAMOO, Riddhi Doshi, Joshua Noone, et al.
Diabetes Therapy (2025)
Open Access
Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study)
Irene Caballero Mateos, María Dolores García de Lucas, Viyey Doulatram‐Gamgaram, et al.
Nutrients (2024) Vol. 16, Iss. 15, pp. 2545-2545
Open Access | Times Cited: 1
Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme
Jean‐François Yale, Atheline Major‐Pedersen, Andrei‐Mircea Catarig, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4429-4440
Closed Access | Times Cited: 1
Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis
Gottfried Rudofsky, Markus Menzen, Louis Potier, et al.
Advances in Therapy (2024) Vol. 42, Iss. 2, pp. 788-800
Open Access | Times Cited: 1
Glycemic Control and Body Weight Reduction with Once-Weekly Semaglutide in Colombian Adults with Type 2 Diabetes: Findings from the COLIBRI Study
Dagoberto Serpa-Díaz, Carlos A Llanos-Florez, Ronald Andrés Serrano Uribe, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 6, pp. 1451-1460
Open Access | Times Cited: 1
The role of weight control in the management of type 2 diabetes mellitus: Perspectives on semaglutide
Peter Kurtzhals, Frederik Flindt Kreiner, Rubdeep Singh Bindra
Diabetes Research and Clinical Practice (2023) Vol. 203, pp. 110881-110881
Open Access | Times Cited: 2
Clinical Research on Type 2 Diabetes: A Promising and Multifaceted Landscape
Fernando Gómez-Peralta, Cristina Abreu
Journal of Clinical Medicine (2022) Vol. 11, Iss. 20, pp. 6007-6007
Open Access | Times Cited: 3
REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: Ambispective, multicenter clinical study. Results in the GLP1-experienced cohort
Jersy Cárdenas‐Salas, Roberto Miguel Sierra Poyatos, Bogdana Luiza Luca, et al.
Journal of Diabetes and its Complications (2024) Vol. 38, Iss. 12, pp. 108874-108874
Closed Access
Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study
Tatjana Milenkovikj, Biljana Chekorova Mitreva, Sasha Jovanovska Mishevska, et al.
Diabetes Research and Clinical Practice (2023) Vol. 206, pp. 111018-111018
Open Access | Times Cited: 1
Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP–4i) in US Adults with Type 2 Diabetes
Xi Tan, Yuanjie Liang, Cory Gamble, et al.
Diabetes Therapy (2023) Vol. 15, Iss. 2, pp. 427-445
Open Access | Times Cited: 1
Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia
Daisy C. Buenaventura-Collazos, Andrés Felipe García Ramos, Carlos Mario Balcázar Valencia, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access
Weight Loss of Semaglutide Treatment for Patients With Overweight or Obesity: A Retrospective Observational Study in China
Xin-Hao Zhang, Ai-Xin Wu, Zhicheng Yang, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top